ADA26: Kidney disease analysis given spotlight
At this year’s American Diabetes Association (ADA) congress, while obesity and diabetes treatments took the limelight, there were sessions focused …
Post
-
-
ADA26: T1 and T2 diabetes readouts from Roche, MannKind and Lilly
The past weekend has seen a number of major data presentations at the American Diabetes Association (ADA) conference 2026. While Clinical …
-
ADA26: key obesity readouts from the conference
As the 2026 American Diabetes Association (ADA) conference draws to a close for another year, Clinical Trials Arena gives you …
-
Pfizer reports positive results from Phase IIb trial of berobenatide
Pfizer has reported detailed Phase IIb results for its investigational monthly glucagon-like peptide-1 receptor agonist (GLP-1 RA) peptide, berobenatide (PF’3944), …
-
Novo Nordisk reports Phase II data for zenagamtide in diabetes
Novo Nordisk has reported results from its Phase II study of zenagamtide, an investigational once-weekly subcutaneous treatment, showing statistically significant …
-
Innovent eyes third-line nod for gastric cancer ADC on Phase III PFS hit
Takeda’s $11.4bn bet on assets from Chinese biotech, Innovent Biologics, is showing early signs of paying off, as the latter …
-
ASCO 2026: darovasertib raises the bar in metastatic uveal melanoma
At the American Society of Clinical Oncology (ASCO) Annual Meeting 2026, held on 29 May - 2 June, primary results …
-
Otsuka’s Voyxact preserves kidney function at 12 months
Otsuka Pharmaceutical’s Voyxact (sibeprenlimab-szsi) has preserved kidney function for 12 months in patients with primary IgA nephropathy (IgAN) in a …
-
ASCO26 Podcast: an analyst rundown of the best readouts and key trends
While the 2026 American Society of Clinical Oncology (ASCO) conference may be over for another year, the editorial team at …
-
Novartis reports positive results from Phase III ALIGN trial for IgAN
Novartis has announced final results from the Phase III ALIGN study, highlighting that Vanrafia (atrasentan) slows kidney function decline versus …
-
First patient dosed in Onchilles’ Phase I/II trial of N17350
Onchilles Pharma has dosed the first patient in its Phase I/II clinical trial of N17350, the lead tumour-directed therapeutic candidate, …
-
ASCO 2026: Interim data released for upcoming BRAF and RAS mCRC therapies
Several abstracts and data presentations on emerging clinical research in metastatic colorectal cancer (mCRC) prompted expert interest and discussion at …
-
ASCO 2026: Novel CD5 directed CAR-T therapy for T-ALL/PTCL shows mixed response
Patients with T-cell acute lymphoblastic leukaemia (T-ALL) and the closely related peripheral T-cell lymphoblastic lymphoma (PTCL) represent a group with …
-
Argenx’s Vyvgart shows durability in myositis and Sjögren’s
Argenx’s Vyvgart (efgartigimod alfa-fcab) shows lengthy benefit for myositis and Sjögren’s disease, setting up its anticipated Phase III readouts. The data …
-
EMA and AMA collaborate on Ebola trials amid public health emergency
The European Medicines Agency’s (EMA’s) emergency task force (ETF) is engaging with the African Medicines Agency (AMA) to plan clinical …
